[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555013":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Tennessee","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine","EXPERIMENTAL","Ketamine infusion (0.3 mg\u002Fkg\u002Fhr) to begin 1 hour before wound care, continuing through and for 1 hour following wound care.",[13],"Drug: Ketamine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","0.9% saline to begin 1 hour before wound care, continuing through and for 1 hour following wound care.",[19],"Drug: 0.9% NaCl",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Infusion during wound care",[9],null,{"type":22,"name":27,"description":23,"armGroupLabels":28,"otherNames":29},"0.9% NaCl",[15],[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"David M Hill, Pharm.D.","CONTACT","1-901-545-7100","dhill19@uthsc.edu",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Regional One Health","RECRUITING","Memphis","Tennessee","38103","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-90.04898,35.14953,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":54,"phoneExt":25,"email":55},"Yvonne Shaw, RN","901-448-2714","yshaw@uthsc.edu",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100555013","phase-4-low-dose-ketamine-infusion-during-burn-wound-care-100555013",false,"NCT06506565","Low-Dose Ketamine Infusion During Burn Wound Care","A Randomized, Placebo-Controlled, Double-Blind Evaluation of Low-Dose Ketamine Infusion During Burn Wound Care Procedures to Improve Pain Intensity and Reduce Opioid Consumption","IMPROVE","Inclusion Criteria:\n\n* Admitted to burn service with thermal injury\n\nExclusion Criteria:\n\n* unable\u002Funwilling to consent within 72 hours\n* unable to report NRS\n* known contraindication to ketamine\n* \\\u003C than 18 years of age\n* pregnant\n* incarcerated\n* TBSA over 50 %","ALL","18 Years",{"count":69,"type":70},140,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","The current standard of care (SOC) (i.e. fentanyl and midazolam) offers limited efficacy for preventing or relieving pain. Ketamine infusions may provide the benefits of analgesia, minimize adverse events, and reduce opioid use. The purpose of this study is to determine if adding a low dose ketamine infusion during wound care will safely provide pain relief for patients with burn injury.",[76,77,78,79],"Burn","Pain","Dissociation","Opioid",[81,82,83,84],"ketamine","burn","opioid","analgesia","2024-12-09",{"date":87,"type":88},"2024-12-13","ACTUAL",{"date":90,"type":88},"2024-07-08",{"date":92,"type":70},"2025-12",{"name":5,"class":6},1]